Financial Assistance Department Physician Office EMR BEACON EMR Social Media HIPAA Disclaimer Site Map Contact Us
BayCare Health System
Careers Find Us Classes & Events Find A Physician Dr.BayCare.org Community Benefit
Quality Report Card About Us Hospitals Services & Programs News Health Tools & Articles
Jak2 V617F Mutation
 Back  Back


May We Help You?
 

Call 1-877-692-2922
Monday-Friday, 8 am to 5pm

Request call-back
Send 
e-mail
Search jobs


Decrease (-) Restore Default Increase (+) Font Size
Print    Email

Jak2 V617F Mutation

Test name:
Jak2 V617F mutation

Order name:
JAK2

Specimen requirements:
EDTA peripheral blood or bone marrow

Minimum volume:
0.5mL.

Storage and stability information:
Room temperature, 1 week

Test performed:
Once per week

Methodology:
Real-time Polymerase Chain Reaction (PCR)

Reference range:
Negative for the Jak2 V617F mutation

Clinical significance:
The mutation affecting the Janus Tyrosine Kinase 2 (JAK2 V617F) is the most common molecular abnormality in chronic Myeloproliferative Disorders (MPD). The highest mutation frequency occurs in patients with PV (Polycythemia Vera, >90%) or ET (Essential Thrombocythemia, 35% to 70%); the lowest frequency is in PMF patients (Primary Myelofibrosis, 50%).

CPT codes:
81270


Serving The Tampa Bay Area © Copyright 2013 BayCare Health System